Atossa Genetics Inc diskutieren
Atossa Genetics Inc
WKN: A2JJ99 / Symbol: ATOS / Name: Atossa Genetics / Aktie / Ausrüstung & Versorgung / Micro Cap /
1,24 €
2,92 %
Atossa Therapeutics, Inc. (NASDAQ: ATOS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for ATOS provided by MarketBeat
Atossa Therapeutics, Inc. (NASDAQ: ATOS) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Ratings data for ATOS provided by MarketBeat
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for ATOS provided by MarketBeat
Atossa Therapeutics, Inc. (NASDAQ: ATOS) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $4.00 price target on the stock.
Ratings data for ATOS provided by MarketBeat
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Ratings data for ATOS provided by MarketBeat
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Ratings data for ATOS provided by MarketBeat
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its price target raised by analysts at HC Wainwright from $4.00 to $6.00. They now have a "buy" rating on the stock.
Ratings data for ATOS provided by MarketBeat
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for ATOS provided by MarketBeat
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its price target raised by analysts at Ascendiant Capital Markets from $6.00 to $6.25. They now have a "buy" rating on the stock.
Ratings data for ATOS provided by MarketBeat
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for ATOS provided by MarketBeat
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Ratings data for ATOS provided by MarketBeat
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Ratings data for ATOS provided by MarketBeat
Neueste Beiträge
StockNews_com in Discuss Malibu Boats Inc. A